Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. H-CYTE, Inc.
  6. News
  7. Summary
    HCYT   US4041241096

H-CYTE, INC.

(HCYT)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

H CYTE : Robert Greif named Chief Executive Officer of H-CYTE

09/29/2020 | 05:31pm EDT

TAMPA, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a developer of regenerative cellular therapeutics, announced today that Robert Greif has been named the company’s new chief executive officer.

“Robert brings decades of pharmaceutical experience to H-CYTE, having successfully taken more than a dozen products from discovery to commercialization,” said Ray Monteleone, H-CYTE board member and chair of the CEO search committee. “We believe he possesses the crucial skill sets necessary to oversee the potential transformation of H-CYTE into a leading biotech company, focused on innovation and meaningful patient outcomes.”

“I am honored to be joining the H-CYTE team to innovate and implement novel growth strategies in our biologics development,” said Greif. “With a focus on evidence-based medicine, it is my hope for H-CYTE to immediately begin clinical research and development of a diverse pipeline of next-generation regenerative therapeutics to meet the needs of patients with a variety of diseases and chronic health conditions.”

Greif joins H-CYTE with a strong track record leading high-growth pharmaceutical and biotech businesses. Most recently, he was Chief Commercial Officer and Business Development Leader at Atox Bio, where he built the North American commercial organization in preparation for the launch of a first-in-class immunomodulator. Prior to that, he led the Commercial Operations of rEVO Biologics, an orphan disease biotechnology company. He has also held a variety of business unit and commercial leadership roles at United Health Group, Boehringer Ingelheim and Sanofi.

Greif joins H-CYTE as CEO and President effective immediately. He replaces William E. Horne, who is stepping down as CEO but will remain on the company’s Board of Directors.

“We are thrilled to have someone with Robert’s background and experience join H-CYTE as our new CEO, especially as we transition to a biotech company,” said Horne. “I look forward to helping the company as a board member, assisting Robert in his transition, and watching H-CYTE thrive and prosper under his leadership.”

About H-CYTE, Inc.
H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions. For more information about H-CYTE, please visit www.HCYTE.com.

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACTS

H-CYTE Media Relations
Sherry Yeaman
syeaman@HCYTE.com
214-725-4315

H-CYTE Investor Relations
Jason Assad
Jassad@HCYTE.com
678-570-6791 


H-Cyte-Logo-Final-CMYK (1).jpg

Source: H-CYTE, Inc.

2020 GlobeNewswire, Inc., source Press Releases

All news about H-CYTE, INC.
04/08H-CYTE, INC.  : Entry into a Material Definitive Agreement, Financial Statements..
AQ
04/07H-CYTE, INC.  : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
03/25H CYTE  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
01/19H-CYTE, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
2020H CYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020H-CYTE, INC.  : Entry into a Material Definitive Agreement, Change in Directors ..
AQ
2020H CYTE  : Robert Greif named Chief Executive Officer of H-CYTE
AQ
2020Robert Greif named Chief Executive Officer of H-CYTE
GL
2020H-CYTE, INC.  : Unregistered Sale of Equity Securities, Other Events (form 8-K)
AQ
2020H-CYTE EXTENDS RIGHTS OFFERING TO 5 : 00 PM Eastern Time on Friday, September 11..
GL
More news
Financials (USD)
Sales 2020 2,15 M - -
Net income 2020 -6,46 M - -
Net cash 2020 0,47 M - -
P/E ratio 2020 -0,27x
Yield 2020 -
Capitalization 4,52 M 4,52 M -
EV / Sales 2019 1,72x
EV / Sales 2020 0,75x
Nbr of Employees -
Free-Float 20,1%
Chart H-CYTE, INC.
Duration : Period :
H-CYTE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert Greif President & Chief Executive Officer
Jeremy Daniel Chief Financial & Accounting Officer
Raymond Monteleone Chairman
Tanya Rhodes Chief Technology Officer
William E. Horne Director
Sector and Competitors
1st jan.Capitalization (M$)
H-CYTE, INC.102.58%5
ABBOTT LABORATORIES8.49%211 353
MEDTRONIC PLC8.67%170 801
BECTON, DICKINSON AND COMPANY-4.33%69 619
ALIGN TECHNOLOGY, INC.11.97%47 351
HOYA CORPORATION-7.88%44 672